144 related articles for article (PubMed ID: 22549049)
1. Measuring net protease activities in biological samples using selective peptidic inhibitors.
Pollaro L; Diderich P; Angelini A; Bellotto S; Wegner H; Heinis C
Anal Biochem; 2012 Aug; 427(1):18-20. PubMed ID: 22549049
[TBL] [Abstract][Full Text] [Related]
2. Bicyclic peptide inhibitor of urokinase-type plasminogen activator: mode of action.
Roodbeen R; Paaske B; Jiang L; Jensen JK; Christensen A; Nielsen JT; Huang M; Mulder FA; Nielsen NC; Andreasen PA; Jensen KJ
Chembiochem; 2013 Nov; 14(16):2179-88. PubMed ID: 24115455
[TBL] [Abstract][Full Text] [Related]
3. The use of chromogenic substrates for the determination of kallikrein and other serine proteases in plasma and synovial fluid in man.
Lewis DH; Bengtsson MB; Liljedahl SO; Larsson J
Adv Biosci; 1978 Jul; 17():163-71. PubMed ID: 158556
[No Abstract] [Full Text] [Related]
4. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).
Katz BA; Luong C; Ho JD; Somoza JR; Gjerstad E; Tang J; Williams SR; Verner E; Mackman RL; Young WB; Sprengeler PA; Chan H; Mortara K; Janc JW; McGrath ME
J Mol Biol; 2004 Nov; 344(2):527-47. PubMed ID: 15522303
[TBL] [Abstract][Full Text] [Related]
5. Characterization of bacterial proteases with a panel of fluorescent peptide substrates.
Wildeboer D; Jeganathan F; Price RG; Abuknesha RA
Anal Biochem; 2009 Jan; 384(2):321-8. PubMed ID: 18957278
[TBL] [Abstract][Full Text] [Related]
6. A novel genetically-encoded bicyclic peptide inhibitor of human urokinase-type plasminogen activator with better cross-reactivity toward the murine orthologue.
Mazzocato Y; Perin S; Morales-Sanfrutos J; Romanyuk Z; Pluda S; Acquasaliente L; Borsato G; De Filippis V; Scarso A; Angelini A
Bioorg Med Chem; 2023 Nov; 95():117499. PubMed ID: 37879145
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of proteases as anticancer drugs.
Jedinak A; Maliar T
Neoplasma; 2005; 52(3):185-92. PubMed ID: 15875078
[TBL] [Abstract][Full Text] [Related]
8. Efficient degradation-aided selection of protease inhibitors by phage display.
Hawinkels LJ; van Rossenberg SM; de Jonge-Muller ES; Molenaar TJ; Appeldoorn CC; van Berkel TJ; Sier CF; Biessen EA
Biochem Biophys Res Commun; 2007 Dec; 364(3):549-55. PubMed ID: 17959143
[TBL] [Abstract][Full Text] [Related]
9. Binding of nonphysiological protein and peptide substrates to proteases: differences between urokinase-type plasminogen activator and trypsin and contributions to the evolution of regulated proteolysis.
Bergstrom RC; Coombs GS; Ye S; Madison EL; Goldsmith EJ; Corey DR
Biochemistry; 2003 May; 42(18):5395-402. PubMed ID: 12731881
[TBL] [Abstract][Full Text] [Related]
10. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
11. A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue.
Andersen LM; Wind T; Hansen HD; Andreasen PA
Biochem J; 2008 Jun; 412(3):447-57. PubMed ID: 18318660
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of the proteolytic activity of urokinase type plasminogen activator.
Rockway TW; Giranda VL
Curr Pharm Des; 2003; 9(19):1483-98. PubMed ID: 12871064
[TBL] [Abstract][Full Text] [Related]
13. Substrate optimization and clinical validation of reporter peptides for MS-based protease profiling in serum specimens: a new approach for diagnosis of malignant disease.
Yepes D; Jacob A; Dauber M; Costina V; Hofheinz R; Neumaier M; Findeisen P
Int J Oncol; 2011 Jul; 39(1):145-54. PubMed ID: 21503574
[TBL] [Abstract][Full Text] [Related]
14. Chromogenic peptide substrates. Their use for the assay of factors in the fibrinolytic and the plasma kallikrein-kinin systems.
Friberger P
Scand J Clin Lab Invest Suppl; 1982; 162():1-298. PubMed ID: 6221396
[No Abstract] [Full Text] [Related]
15. Engineering bidentate macromolecular inhibitors for trypsin and urokinase-type plasminogen activator.
Yang SQ; Craik CS
J Mol Biol; 1998 Jun; 279(4):1001-11. PubMed ID: 9642077
[TBL] [Abstract][Full Text] [Related]
16. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
17. Fluorogenic peptide substrates for proteases in blood coagulation, kallikrein-kinin and fibrinolysis systems.
Iwanaga S; Morita T; Kato H; Harada T; Adachi N; Sugo T; Maruyama I; Takada K; Kimura T; Sakakibara S
Adv Exp Med Biol; 1979; 120A():147-63. PubMed ID: 158955
[No Abstract] [Full Text] [Related]
18. Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis.
Ostrowski LE; Ahsan A; Suthar BP; Pagast P; Bain DL; Wong C; Patel A; Schultz RM
Cancer Res; 1986 Aug; 46(8):4121-8. PubMed ID: 3089587
[TBL] [Abstract][Full Text] [Related]
19. Structural Principles in the Development of Cyclic Peptidic Enzyme Inhibitors.
Xu P; Andreasen PA; Huang M
Int J Biol Sci; 2017; 13(10):1222-1233. PubMed ID: 29104489
[TBL] [Abstract][Full Text] [Related]
20. Effects of Pseudomonas fluorescens M3/6 bacterial protease on plasmin system and plasminogen activation.
Frohbieter KA; Ismail B; Nielsen SS; Hayes KD
J Dairy Sci; 2005 Oct; 88(10):3392-401. PubMed ID: 16162512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
